Category Archives: Psoriasis

Psoriasis TreatmentMarket 2020: Inclusive Insight

Los Angeles, United States,July 2020:The report titled Global Psoriasis Treatment Market is one of the most comprehensive and important additions to Alexareports archive of market research studies. It offers detailed research and analysis of key aspects of the global Psoriasis Treatment market. The market analysts authoring this report have provided in-depth information on leading growth drivers, restraints, challenges, trends, and opportunities to offer a complete analysis of the global Psoriasis Treatment market. Market participants can use the analysis on market dynamics to plan effective growth strategies and prepare for future challenges beforehand. Each trend of the global Psoriasis Treatment market is carefully analyzed and researched about by the market analysts.

Psoriasis Treatment Market competition by top manufacturers/ Key player Profiled: Novartis International AG, Johnson & Johnson, Pfizer Inc., Merck and Co. Inc., AbbVie and Amgen, Eli Lilly

Get PDF Sample Copy of the Report to understand the structure of the complete report:(Including Full TOC, List of Tables & Figures, Chart) : https://www.alexareports.com/report-sample/927174

Global Psoriasis Treatment Market is estimated to reach xxx million USD in 2020 and projected to grow at the CAGR of xx% during 2020- 2025. According to the latest report added to the online repository of Alexareports the Psoriasis Treatment market has witnessed an unprecedented growth till 2020. The extrapolated future growth is expected to continue at higher rates by 2025.

Based on region, the globalPsoriasis Treatment market has been segmented into Americas (North America ((the U.S. and Canada),) and Latin Americas), Europe (Western Europe (Germany, France, Italy, Spain, UK and Rest of Europe) and Eastern Europe), Asia Pacific (Japan, India, China, Australia & South Korea, and Rest of Asia Pacific), and Middle East & Africa (Saudi Arabia, UAE, Kuwait, Qatar, South Africa, and Rest of Middle East & Africa).

Psoriasis Treatment Market Segment by Type covers: TNF Inhibitors, Phosphodiesterase Inhibitors, Interleukin Blockers

Psoriasis Treatment Market Segment by Industry: Oral, Tropical, Injectable

After reading the Psoriasis Treatment market report, readers get insight into:

*Major drivers and restraining factors, opportunities and challenges, and the competitive landscape*New, promising avenues in key regions*New revenue streams for all players in emerging markets*Focus and changing role of various regulatory agencies in bolstering new opportunities in various regions*Demand and uptake patterns in key industries of the Psoriasis Treatment market*New research and development projects in new technologies in key regional markets*Changing revenue share and size of key product segments during the forecast period*Technologies and business models with disruptive potential

Key questions answered in the report:

What will the market growth rate of Psoriasis Treatment market?What are the key factors driving the global Psoriasis Treatment market size?Who are the key manufacturers in Psoriasis Treatment market space?What are the market opportunities, market risk and market overview of the Psoriasis Treatmentmarket?What are sales, revenue, and price analysis of top manufacturers of Psoriasis Treatment market?Who are the distributors, traders, and dealers of Psoriasis Treatment market?What are the Psoriasis Treatment market opportunities and threats faced by the vendors in the global Psoriasis Treatmentindustries?What are sales, revenue, and price analysis by types and applications of Psoriasis Treatmentmarket?What are sales, revenue, and price analysis by regions of Psoriasis Treatment industries?

Get a discount on this report now at https://www.alexareports.com/check-discount/927174

Table of ContentsSection 1 Psoriasis Treatment Product DefinitionSection 2 Global Psoriasis Treatment Market Manufacturer Share and Market Overview2.1 Global Manufacturer Psoriasis Treatment Shipments2.2 Global Manufacturer Psoriasis Treatment Business Revenue2.3 Global Psoriasis Treatment Market Overview2.4 COVID-19 Impact on Psoriasis Treatment IndustrySection 3 Manufacturer Psoriasis Treatment Business Introduction3.1 Novartis International AG Psoriasis Treatment Business Introduction3.1.1 Novartis International AG Psoriasis Treatment Shipments, Price, Revenue and Gross profit 2015-20203.1.2 Novartis International AG Psoriasis Treatment Business Distribution by Region3.1.3 Novartis International AG Interview Record3.1.4 Novartis International AG Psoriasis Treatment Business Profile3.1.5 Novartis International AG Psoriasis Treatment Product Specification3.2 Johnson & Johnson Psoriasis Treatment Business Introduction3.2.1 Johnson & Johnson Psoriasis Treatment Shipments, Price, Revenue and Gross profit 2015-20203.2.2 Johnson & Johnson Psoriasis Treatment Business Distribution by Region3.2.3 Interview Record3.2.4 Johnson & Johnson Psoriasis Treatment Business Overview3.2.5 Johnson & Johnson Psoriasis Treatment Product Specification3.3 Pfizer Inc. Psoriasis Treatment Business Introduction3.3.1 Pfizer Inc. Psoriasis Treatment Shipments, Price, Revenue and Gross profit 2015-20203.3.2 Pfizer Inc. Psoriasis Treatment Business Distribution by Region3.3.3 Interview Record3.3.4 Pfizer Inc. Psoriasis Treatment Business Overview3.3.5 Pfizer Inc. Psoriasis Treatment Product Specification3.4 Merck and Co. Inc. Psoriasis Treatment Business Introduction3.5 AbbVie and Amgen Psoriasis Treatment Business Introduction3.6 Eli Lilly Psoriasis Treatment Business IntroductionSection 4 Global Psoriasis Treatment Market Segmentation (Region Level)4.1 North America Country4.1.1 United States Psoriasis Treatment Market Size and Price Analysis 2015-20204.1.2 Canada Psoriasis Treatment Market Size and Price Analysis 2015-20204.2 South America Country4.2.1 South America Psoriasis Treatment Market Size and Price Analysis 2015-20204.3 Asia Country4.3.1 China Psoriasis Treatment Market Size and Price Analysis 2015-20204.3.2 Japan Psoriasis Treatment Market Size and Price Analysis 2015-20204.3.3 India Psoriasis Treatment Market Size and Price Analysis 2015-20204.3.4 Korea Psoriasis Treatment Market Size and Price Analysis 2015-20204.4 Europe Country4.4.1 Germany Psoriasis Treatment Market Size and Price Analysis 2015-20204.4.2 UK Psoriasis Treatment Market Size and Price Analysis 2015-20204.4.3 France Psoriasis Treatment Market Size and Price Analysis 2015-20204.4.4 Italy Psoriasis Treatment Market Size and Price Analysis 2015-20204.4.5 Europe Psoriasis Treatment Market Size and Price Analysis 2015-20204.5 Other Country and Region4.5.1 Middle East Psoriasis Treatment Market Size and Price Analysis 2015-20204.5.2 Africa Psoriasis Treatment Market Size and Price Analysis 2015-20204.5.3 GCC Psoriasis Treatment Market Size and Price Analysis 2015-20204.6 Global Psoriasis Treatment Market Segmentation (Region Level) Analysis 2015-20204.7 Global Psoriasis Treatment Market Segmentation (Region Level) AnalysisSection 5 Global Psoriasis Treatment Market Segmentation (Product Type Level)5.1 Global Psoriasis Treatment Market Segmentation (Product Type Level) Market Size 2015-20205.2 Different Psoriasis Treatment Product Type Price 2015-20205.3 Global Psoriasis Treatment Market Segmentation (Product Type Level) AnalysisSection 6 Global Psoriasis Treatment Market Segmentation (Industry Level)6.1 Global Psoriasis Treatment Market Segmentation (Industry Level) Market Size 2015-20206.2 Different Industry Price 2015-20206.3 Global Psoriasis Treatment Market Segmentation (Industry Level) AnalysisSection 7 Global Psoriasis Treatment Market Segmentation (Channel Level)7.1 Global Psoriasis Treatment Market Segmentation (Channel Level) Sales Volume and Share 2015-20207.2 Global Psoriasis Treatment Market Segmentation (Channel Level) AnalysisSection 8 Psoriasis Treatment Market Forecast 2020-20258.1 Psoriasis Treatment Segmentation Market Forecast (Region Level)8.2 Psoriasis Treatment Segmentation Market Forecast (Product Type Level)8.3 Psoriasis Treatment Segmentation Market Forecast (Industry Level)8.4 Psoriasis Treatment Segmentation Market Forecast (Channel Level)Section 9 Psoriasis Treatment Segmentation Product Type9.1 TNF Inhibitors Product Introduction9.2 Phosphodiesterase Inhibitors Product Introduction9.3 Interleukin Blockers Product IntroductionSection 10 Psoriasis Treatment Segmentation Industry10.1 Oral Clients10.2 Tropical Clients10.3 Injectable ClientsSection 11 Psoriasis Treatment Cost of Production Analysis11.1 Raw Material Cost Analysis11.2 Technology Cost Analysis11.3 Labor Cost Analysis11.4 Cost OverviewSection 12 Conclusion

Do Inquiry About The Report Here: https://www.alexareports.com/send-an-enquiry/927174

About Us:Alexa Reports is a globally celebrated premium market research service provider, with a strong legacy of empowering business with years of experience. We help our clients by implementing decision support system through progressive statistical surveying, in-depth market analysis, and reliable forecast data.

Contact Us:Alexa ReportsPh no: +1-408-844-4624Email: [emailprotected]Site: https://www.alexareports.com

More here:
(2020-2025) Psoriasis Treatment Market Estimated To Experience A Hike in Growth | Global Industry Size, Growth, Segments, Revenue, Manufacturers -...

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Psoriatic Arthritis Drugs Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Psoriatic Arthritis Drugs market.

The research study includes the latest updates about the COVID-19 impact on the Psoriatic Arthritis Drugs sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Avail Your Copy of the Sample of the Psoriatic Arthritis Drugs Market Report @ https://www.marketresearchintellect.com/download-sample/?rid=201953&utm_source=3WN&utm_medium=888

Leading Psoriatic Arthritis Drugs manufacturers/companies operating at both regional and global levels:

The report also inspects the financial standing of the leading companies, which includes gross profit, revenue generation, sales volume, sales revenue, manufacturing cost, individual growth rate, and other financial ratios.

Industrial Analysis:

The Psoriatic Arthritis Drugs market report is extensively categorized into different product types and applications. The study has a separate section for explaining the cost of raw material and the revenue returns that are gained by the players of the market.

The segmentation included in the report is beneficial for readers to capitalize on the selection of appropriate segments for the Psoriatic Arthritis Drugs sector and can help companies in deciphering the optimum business move to reach their desired business goals.

In Market Segmentation by Types of Psoriatic Arthritis Drugs, the report covers-

In Market Segmentation by Applications of the Psoriatic Arthritis Drugs, the report covers the following uses-

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=201953&utm_source=3WN&utm_medium=888

The Psoriatic Arthritis Drugs market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Psoriatic Arthritis Drugs market.

This study analyzes the growth of Psoriatic Arthritis Drugs based on the present, past and futuristic data and will render complete information about the Psoriatic Arthritis Drugs industry to the market-leading industry players that will guide the direction of the Psoriatic Arthritis Drugs market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Psoriatic Arthritis Drugs market. Additionally, it includes a share of each segment of the Psoriatic Arthritis Drugs market, giving methodical information about types and applications of the market.

Reasons for Buying Psoriatic Arthritis Drugs Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Psoriatic Arthritis Drugs market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=201953&utm_source=3WN&utm_medium=888

In the end, the Psoriatic Arthritis Drugs market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Psoriatic Arthritis Drugs market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Engineered Fluids Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Seam Tapes Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Interventional Oncology Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Medical Vacuum System Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Medical Equipment Cooling Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Read this article:
Psoriatic Arthritis Drugs Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

EXTON, Pa., July 2, 2020 /PRNewswire/ -- Over the past four years, multiple new agents have been FDA approved for the treatment of psoriatic arthritis (PsA), including Pfizer's Xeljanz, Eli Lilly's Taltz, BMS' Orencia, and Janssen's Simponi Aria. In addition, the development pipeline is ripe with many new agents offering novel mechanism approaches, including UCB's bimekizumab and BMS' TYK2 inhibitor (BMS-986165), that will join likely PsA line extensions of Janssen's Tremfya, Sun Pharma's Ilumya, and AbbVie's Rinvoq and Skyrizi.

Each year, Spherix Global Insights collaborates with approximately 200 rheumatologists to conduct large scale, retrospective patient chart audits, exclusively focusing on recent trends in PsA switching patterns. The 2020 audit, which was released last week, highlights recent switching patterns for 1,008 patients with PsA who are being treated with a biologic, JAK inhibitor, or Amgen's Otezla. Notably, this is the first year that Otezla is under Amgen's domain, after being divested by Celgene in accordance with the acquisition by BMS.

At the end of 2015, switching patterns in PsA were still largely driven by TNF inhibitor sequencing, with more than one-half of the recent switches occurring within the class. In each sequential year, TNF cycling eroded, with the most recent results indicating that fewer than one-in-four of patients are now treated with two consecutive TNFs. Collectively, the IL-17s (Novartis' Cosentyx and Eli Lilly's Taltz) grew switching share from virtually nothing in late 2015 to approximately one-quarter of switches in the present audit. The approval of Xeljanz for PsA in December 2017 also caused some disruption, introducing an oral challenger to Otezla. Switches both from and to oral agents increased substantially since the first edition of this study several years ago.

Rheumatologists have consistently reported that among their PsA patients being treated with biologics or advanced small molecules, slightly more than one-quarter are switched in any given year, making the competition for second-line agents fierce. There is less opportunity for later-line switching, making it critical to be positioned as the first-line or first-switch brand. An evaluation of first-line treatment among patients who ultimately switched indicates dwindling first-line use of Amgen's Enbrel over the past three years, but an uptick in Otezla keeping the company's portfolio largely net neutral in first-line use.

However, since late 2015, Enbrel and Otezla have collectively forfeited second-line share, dropping from 38% to 21% over the four-year period. Furthermore, Enbrel was poised to capture an incremental 9% of the recent switches, ultimately losing out to AbbVie's Humira most frequently, but also losing to Amgen's own Otezla in more than 10% of the cases. Market access seems to be helping Enbrel stay in the game in more than half of the cases where patients were switched to Enbrel, the rheumatologist would have selected a different agent if market access were not a factor.

As expected, most switching is based on the desire for improved efficacy in joints, but often the decision is multi-factorial, with rheumatologists reporting that patients themselves are often the drivers in more than one-quarter of the cases. The reasons for selection of the new agent vary by mechanism of action and brand, with Xeljanz and Otezla benefitting from patient requests and a desire for the oral formulation. Humira and Enbrel are often selected based on habit, while others stake a claim on specific patient types: Orencia for patients with multiple co-morbidities; Taltz when skin efficacy is desired; and Cimzia when family planning considerations are at play.

The market will soon be crowded with even more treatment options. Rheumatologists report the greatest familiarity with AbbVie's Rinvoq for PsA, which was approved last August and has had a meteoric rise in rheumatoid arthritis (see RealTime Dynamix: Rheumatoid Arthritis (US)). Comparably, there is less familiarity with bimekizumab, Tremfya, Skyrizi, Ilumya, and BMS-986165. Rinvoq looks to pose the greatest threat to Xeljanz; bimekizumab to the IL-17s; and Tremfya to Cosentyx and Janssen's own Stelara.

Being positioned clinically (with strong joint efficacy data) and from a market access perspective to compete in the first- or second-line position is critical to optimizing performance in the PsA market. Secondary strategies include being able to carve out a sizable patient profile niche and/or driving patient requests through DTC and the development of patient-preferred formulations.

About RealWorld DynamixRealWorld Dynamix: Biologic/Small Molecule Switching in PsA (US) is an independent, data-driven service unmasking real patient management patterns through annual reports based on chart audits of ~1,000 patients. The report uncovers the "why" behind treatment decisions, includes year over year trending to quantify key aspects of market evolution, and integrates specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns.

About Spherix Global InsightsSpherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.

All company, brand or product names in this document are trademarks of their respective holders.

For more information contact:Kristen Henn, Business Development ManagerEmail:info@spherixglobalinsights.comwww.spherixglobalinsights.com

Continued here:
Massive Shift in Practice Patterns in Psoriatic Arthritis as Rheumatologists Lean Toward Increased Use of JAK inhibitors and Novel Biologics - WFMZ...

New Jersey, United States,- Market Research Intellect sheds light on the market scope, potential, and performance perspective of the Global Psoriasis Drugs Market by carrying out an extensive market analysis. Pivotal market aspects like market trends, the shift in customer preferences, fluctuating consumption, cost volatility, the product range available in the market, growth rate, drivers and constraints, financial standing, and challenges existing in the market are comprehensively evaluated to deduce their impact on the growth of the market in the coming years. The report also gives an industry-wide competitive analysis, highlighting the different market segments, individual market share of leading players, and the contemporary market scenario and the most vital elements to study while assessing the global Psoriasis Drugs market.

The research study includes the latest updates about the COVID-19 impact on the Psoriasis Drugs sector. The outbreak has broadly influenced the global economic landscape. The report contains a complete breakdown of the current situation in the ever-evolving business sector and estimates the aftereffects of the outbreak on the overall economy.

Leading Psoriasis Drugs manufacturers/companies operating at both regional and global levels:

To get Incredible Discounts on this Premium Report, Click Here @ https://www.marketresearchintellect.com/ask-for-discount/?rid=190153&utm_source=3WN&utm_medium=888

The Psoriasis Drugs market report provides successfully marked contemplated policy changes, favorable circumstances, industry news, developments, and trends. This information can help readers fortify their market position. It packs various parts of information gathered from secondary sources, including press releases, web, magazines, and journals as numbers, tables, pie-charts, and graphs. The information is verified and validated through primary interviews and questionnaires. The data on growth and trends focuses on new technologies, market capacities, raw materials, CAPEX cycle, and the dynamic structure of the Psoriasis Drugs market.

This study analyzes the growth of Psoriasis Drugs based on the present, past and futuristic data and will render complete information about the Psoriasis Drugs industry to the market-leading industry players that will guide the direction of the Psoriasis Drugs market through the forecast period. All of these players are analyzed in detail so as to get details concerning their recent announcements and partnerships, product/services, and investment strategies, among others.

Sales Forecast:

The report contains historical revenue and volume that backing information about the market capacity, and it helps to evaluate conjecture numbers for key areas in the Psoriasis Drugs market. Additionally, it includes a share of each segment of the Psoriasis Drugs market, giving methodical information about types and applications of the market.

Reasons for Buying Psoriasis Drugs Market Report

This report gives a forward-looking prospect of various factors driving or restraining market growth.

It renders an in-depth analysis for changing competitive dynamics.

It presents a detailed analysis of changing competition dynamics and puts you ahead of competitors.

It gives a six-year forecast evaluated on the basis of how the market is predicted to grow.

It assists in making informed business decisions by performing a pin-point analysis of market segments and by having complete insights of the Psoriasis Drugs market.

This report helps the readers understand key product segments and their future.

Have Any Query? Ask Our Expert @ https://www.marketresearchintellect.com/need-customization/?rid=190153&utm_source=3WN&utm_medium=888

In the end, the Psoriasis Drugs market is analyzed for revenue, sales, price, and gross margin. These points are examined for companies, types, applications, and regions.

To summarize, the global Psoriasis Drugs market report studies the contemporary market to forecast the growth prospects, challenges, opportunities, risks, threats, and the trends observed in the market that can either propel or curtail the growth rate of the industry. The market factors impacting the global sector also include provincial trade policies, international trade disputes, entry barriers, and other regulatory restrictions.

About Us:

Market Research Intellect provides syndicated and customized research reports to clients from various industries and organizations with the aim of delivering functional expertise. We provide reports for all industries including Energy, Technology, Manufacturing and Construction, Chemicals and Materials, Food and Beverage, and more. These reports deliver an in-depth study of the market with industry analysis, the market value for regions and countries, and trends that are pertinent to the industry.

Contact Us:

Mr. Steven Fernandes

Market Research Intellect

New Jersey ( USA )

Tel: +1-650-781-4080

Our Trending Reports

Hexamethylene Diamine Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Solvents Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Methyl Ester Ethoxylate Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Automotive AfterMarket Fuel Additives Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Antifreeze/Coolant Market Size, Growth Analysis, Opportunities, Business Outlook and Forecast to 2026

Here is the original post:
Psoriasis Drugs Market Growth By Manufacturers, Type And Application, Forecast To 2026 - 3rd Watch News

New data from a head-to-head study comparing risankizumab-rzaa to secukinumab in patients with moderate to severe plaque psoriasis were recently presented online at the American Academy of Dermatology virtual annual meeting.

In this 52-week, phase 3b, open-label, active-comparator study, patients were randomized to receive risankizumab 150mg subcutaneously (n=164) at baseline, week 4, then every 12 weeks thereafter, or secukinumab 300mg subcutaneously at baseline, weeks 1, 2, 3, and 4, then every 4 weeks thereafter. The co-primary end points were the proportion of patients with a 90% reduction in the Psoriasis Area and Severity Index score (PASI 90 response) at week 16 (noninferiority) and at week 52 (superiority) from baseline.

Results showed that the study met both primary end points of noninferiority and superiority. A greater proportion of patients treated with risankizumab achieved a PASI 90 response at week 16 (74% vs 66%) and at week 52 (87% vs 57%; P <.001) compared with secukinumab.

Risankizumab also met key secondary end points including a superior rate of complete skin clearance (PASI 100 response) at week 52 compared with secukinumab (66% vs 40%; P <.001). Moreover, 88% of patients treated with risankizumab achieved a static Physician Global Assessment (sPGA) score of clear (0) or almost clear (1) at week 52 compared with 58% of patients treated with secukinumab (P <.001).

Risankizumab and secukinumab demonstrated comparable rates of adverse reactions. The most common were nasopharyngitis, upper respiratory tract infection, headache, arthralgia and diarrhea.

Risankizumab, an interleukin-23 antagonist, is marketed under the trade name Skyrizi and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy.

Secukinumab, an interleukin-17A antagonist, is marketed under the trade name Cosentyx and is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. It is also approved for the treatment of active psoriatic arthritis or ankylosing spondylitis in adults.

For more information visit abbvie.com.

Read the original here:
Superior Skin Clearance Observed With Risankizumab in Head-to-Head Psoriasis Study - Monthly Prescribing Reference

On this page:BasicsTopical MedicationsOral TreatmentsBiologics

Theres no cure for psoriasis, but there are a lot of medications that can treat the chronic skin condition. Whether youre newly diagnosed or still searching for the right treatment (yup, sometimes theres a little trial and error), the number of choices can seem daunting. There are topicals, oral medications, and biologic drugs. While they all have the same overall goalclear your skinthey do it in different ways. Some medications soothe and calm an outbreak, while others prevent future flares. The treatment plan you end up on is often determined by your type of psoriasis, its severity and location, and your overall healthy history. Here, well walk you through all your options.

Psoriasis is a chronic condition that causes red, stinging patches or bumps on your arms, legs, and even your scalp. When you have this disease, your skin cells turn over faster than they should, leading to a buildup of cells on your body's surface that turn into those inflamed, scaly spots.

At first glance, it looks like a skin issue. And while thats true, experts say it starts on a deeper levelin your immune system. An overactive immune system, along with a genetic predisposition for psoriasis, and at least one other factor such as infection, obesity, or smoking are thought to be the driving forces behind the condition.

As we mentioned, there are several different types of psoriasis: plaque psoriasis (the most common type), scalp psoriasis, guttate, pustular, inverse, erythrodermic, and even psoriatic arthritis, which is a combo of psoriasis and arthritis. The medication youre prescribed is often determined by your type, and may include topical treatments, drugs taken orally, and injections. Let's start by taking a look at topical medications for psoriasis.

These creams, ointments, foams, shampoos, and lotions are applied directly to the affected areas, and are often prescribed for mild to moderate casespsoriasis that covers 1% to 10% of your body. Topical treatments can be used alone, or in combination with another treatment prescribed by your doctor. For example, you may use a cream along with an oral medication and/or light therapy. Topicals are used for these types of psoriasis:

The most common types of topical treatments prescribed for psoriasis include:

Corticosteroids work by reducing inflammation and redness. Theyre often prescribed to clear a current flare but wont necessarily stop your psoriasis from coming back in the future. There are various forms, including liquids, foams, and creams that come in various strengths. Examples include:

Side effects include:

These creams, liquids, and foams are believed to stop the overgrowth of skin cells, which may help prevent future psoriasis flares. They also help clear current patches by sloughing off scaly skin and flattening plaques so they are less noticeable.

Dovonex (calcipotriene) is a synthetic form of vitamin D that comes in a cream or a liquid for scalp psoriasis. You apply it twice a day for up to eight weeks.

Vectical (calcitriol) is a natural form of vitamin D that comes in an ointment formulation to use twice daily. While most topicals are okay to use during pregnancy, Vectical is not.

Enstilar (calcipotriene and betamethasone dipropionate) is a foam thats a combination of a synthetic form of vitamin D and a steroid. Its approved for adults only and used once a day for up to a month.

Taclonex (calcipotriene and betamethasone dipropionate) is a liquid vitamin D-steroid combo thats approved for use in children ages 12 and up. Use it once a day for up to a month.

Research has shown that using a vitamin D analogue with a corticosteroid may not only be more effective than using either one alone, but the combo can even reduce the side effects that can come with strong steroid use. But side effects can include:

Yes, the vitamin A derivatives that smooth wrinkles and clear acne can also help with psoriasis. Topical retinoids help alleviate redness, scaling, and inflammation, and regulate the high-speed skin-cell growth associated with the condition. Because of their risk of birth defects, retinoids should be avoided if youre pregnant or planning to become pregnant.

Tazorac (tazarotene), available as a gel or cream, is approved for adults and comes in two strengths. It is used once a day and can be applied daily for up to a year.

Duobril (halobetasol propionate and tazarotene) is one of the newest topical medications. This combo product contains a vitamin A derivative (called tazarotene) with an anti-inflammatory cream. You use it daily as needed.

Side effects include:

Anthralin is a man-made version of goa powder, a natural substance that comes from the araroba tree. Like many of the other topicals, this helps halt the excessive growth of skin cells and is approved for adults. It comes in a variety of formulations including a cream, ointment, and paste which can be used once a day on the skin. It also comes in a shampoo which can be used on the scalp. Anthralin-containing products include:

Side effects include:

Taken by mouth, oral medications target your overactive immune system (or parts of it) to reduce inflammation and/or slow down skin cell production. With so many choices, your doctor can help you find the best oral option for you to take alone or in combination with other forms of treatment like topicals, phototherapy, or biologics. Oral medications are most often prescribed for the following psoriasis types:

The most commonly prescribed oral options include:

Trexall and Rheumatrex (methotrexate) work by targeting and slowing the growth of skin cells. They come with a risk of toxicity, so theyre only taken once or twice a week, and not prescribed for long-term use. Methotrexate isnt safe to take if youre pregnant or nursing or have any blood issues like low white blood cell count or anemia.

Side effects include:

Gengraf (cyclosporine) was initially used as a medication to ward off organ rejection. It works on severe psoriasis by slowing an overactive immune system. The drug is taken daily either in pill form or a liquid that you dilute in juice.

Side effects: Cyclosporine can cause decreased kidney function, flu-like symptoms, high blood pressure, and cholesterol. This is another medication thats not safe while pregnant or nursing, and shouldnt be taken for longer than a year. Avoid cyclosporine if you take anti-cancer, anti-fungal, anti-convulsants, or anti-inflammatory medications, as well as antibiotics, aspirin, or ibuprofen.

Xeljanz (tofacitinib), one of the newer oral medications, inhibits a family of intracellular nonreceptors called Janus kinase, a.k.a. a JAK inhibitor. In doing so, it decreases cytokines, proteins that cause inflammation. By lowering inflammation in those with psoriasis, you get less symptoms.

Side effects include:

Soriatane (acitretin) is a form of vitamin A (a.k.a. a retinoid) that helps regulate those out-of-control skin cells. Its taken orally daily. If youre pregnant or planning to start a family within the next three years or have experienced sensitivity to retinoids in the past, this medication isnt an option for you.

Side effects include:

Otezla (apremilast) is one of the newest oral treatments. It works by reducing inflammation. Less inflammation may mean less outbreaks, or at least less severe ones. This cant be taken with some other medications such as phenobarbital and rifampin.

Side effects include:

Prednisone and Medrol (methylprednisone). Sometimes prescribed as pills or injections, these meds work by reducing inflammation and slowing cell growth. They help calm a flare-up but arent recommended for long-term use.

Side effects include:

These drugs are commonly prescribed (alone or along with other meds) for moderate-to-severe psoriasis because theyre so effectiveespecially the newer kids on the block like Skyrizi, Cimzia, and Ilumya.

Biologics are known as systemic treatments because they spread throughout the body and do their work from the inside out, but unlike other drugs that affect your entire immune system, these zero in on very specific partsvarious proteins or white blood cells that contribute to psoriasis such as tumor necrosis factor (TNF), interleukin 17, interleukin 23, and T-cells. By blocking these proteins and cells, the drugs can stop a psoriasis flare.

Interestingly, psoriasis biologics may help with other inflammatory issues such as heart disease. A recent study in JAMA Cardiology found that those who took biologics for psoriasis had a significant reduction in coronary inflammation, too.

Biologics are made from living cells of animals, humans, or bacteria and are given through an intravenous drip (IV) or injected in your thigh, upper arm, stomach, or butt either by a health care provider, caregiver, or yourself. (Dont worry, your M.D. will make sure you know exactly how to do this before sending you off to self-inject.)

Theyre used to treat these types of psoriasis:

There are several types of biologics:

Stelara (ustekinumab) is injected into your body to block a protein called IL-23. This helps ease the inflammation that can cause symptoms of both moderate to severe psoriasis and psoriatic arthritis. The drug requires two starter injections four weeks apart followed by four doses done 12 weeks apart.

Ilumya (tidrakizumab-asmn) and Skyrizi (risankizumab-rzaa) require two initial doses, four weeks apart, to block the IL-23 protein. This is followed by four doses per year, every 12 weeks.

Tremfya (guselkumab) also targets IL-23 with two starter doses four weeks apart and then every eight weeks.

Side effects include:

One cause of plaque psoriasis (which accounts for 80% of all psoriasis cases) is the excess production of a protein called tumor necrosis factor (TNF) which tells your skin cells to grow at an accelerated rate. These medications, which block TNF so that your skin cells grow more slowly, need to be taken over a long period of time to clear your skin.

Unlike some psoriasis medications, TNF inhibitors can be taken while pregnant or nursing (but of course, not without talking to your OB/GYN). However, youll want to avoid this category of biologics if you have multiple sclerosis (MS) or have an immediate relative with MS. Anti-TNF therapy has been associated with the demyelinating disease.

Cimzia (certolizumab pegol) can either be injected by yourself or you can have it injected at your doctors offices with two doses the first time, then two doses two weeks later, followed by two doses two weeks after that. Following these initial shots, you have one every other week.

Enbrel (etanercept) is unique because it is also approved for use in children. Although dosage can vary, you typically inject yourself with Enbrel twice a week for the first three months and then once a week for three months after that.

Humira (adalimumab) starts with two doses on day one and continues with one dose every other week. Cyltezo and Amjevita are approved biosimilars to Humira.

Remicade (infliximab) is given as an IV infusion that takes about two hours at your health care providers office. You begin with three starter doses administered during a six-week period, and then get one infusion every eight weeks. Inflectra and Renflexis are biosimilar.

Side effects include:

These biologics contain a human antibody that blocks a protein called interleukin 17 (IL 17), which causes inflammation and an immune response. Before prescribing these biologics, your M.D. will make sure you dont have latent tuberculosis, meaning you carry the tuberculosis bacteria but dont have an active disease. IL 17 inhibitors can trigger a case.

Cosentyx (secukinumab) is self-injected; two doses a week for four weeks and then once a month.

Siliq (brodalumab) targets four of the IL-17 proteins (others target just one). You take one dose weekly for three weeks and then one dose every two weeks. (Siliq carries a warning about suicidal behavior and thoughts.

Taltz (ixekizumab) is self-injected; two doses on the first day and then one injection every two weeks for three months. After that, you do it just once per month.

Side effects include:

These medications target T-cells, a type of white blood cell that causes inflammation.

Orencia (abatacept) is prescribed as a once-a-week shot for psoriatic arthritis, but it doesnt help with skin psoriasis.

Side effects include:

In some cases, your physician may prescribe a biologic along with another medication such as a topical treatment or oral medication. Some people develop anti-drug antibodies (ADAs) to biologics, making them less effective after a while. A review in the British Journal of Dermatology found that combining a biologic with the systemic oral medication methotrexate may help prevent ADAs.

Some medications are safe to take while pregnant or breastfeeding, while others, such as methotrexate, should be avoided. Discuss your options with your doctor so you can create a customized treatment plan.

You may be desperate to try anything to soothe your skin, but skip the fad diets, tanning beds, and Vicks VapoRubtheres little to no research verifying their efficacy, and they can irritate or dry out your skin.

Yes. Many of the medications are approved for both conditions, including the Cimzia, Enbrel, Humira, Stelara, Remicade, Cosentyx, methotrexate, Otezla, and systemic steroids.

Some people notice their biologic doesnt work as well over time. Experts say your body may have outsmarted the drug by creating antibodies against it. If your psoriasis is no longer responding to a certain drug, your doctor will likely switch you to something else.

See the original post here:
What Are the Medication Options for Psoriasis? - HealthCentral.com

Patients with psoriasis often have other physical diseases, and these somatic comorbidities can have a bigger effect on the patients mental health than the skin symptoms from their psoriasis, according to a study published in JAMA Dermatology.

Researchers in Sweden used a population-based registry data from Swedish patients in routine clinical care. Patients with psoriasis were matched with control participants without psoriasis by age, sex, and municipality. All participants in the study were free of existing psychiatric illness (PI).

Little is known about the independent risks imparted by skin psoriasis compared with somatic comorbidity on the development of PI or whether they have additive or synergistic associations, the authors explained.

A total of 93,239 patients with skin psoriasis and 1,387,495 control participants were enrolled between January 2005 and December 2010. Patients with psoriasis had their first diagnosis during the study period. For the study, PI was a composite measure of depression, anxiety, and suicidality, which was composed of suicidal ideation, suicide attempt, and completed suicide. The Elixhauser Comorbidity Index (ECI) and the Charlson Comorbidity Index (CCI) were used to calculate comorbidity profiles for each patient in the year before baseline.

The authors found that the interaction between skin psoriasis and ECI and between skin psoriasis and CCI were not statistically significant, which indicated skin psoriasis and somatic comorbidities do not act synergistically. The authors noted that both skin psoriasis and somatic comorbidity are independent risk factors for PI onset.

Patients who were sicker (with both skin psoriasis and somatic comorbidity) had the highest rate of incident PI. However, patients with skin psoriasis but no somatic comorbidity actually had a lower rate of PI onset compared with the control participants who had somatic comorbidity.

The authors speculated that the somatic comorbidities in the ECI and CCI may be considered severe compared with skin psoriasis, which explains why they may contribute more to PI onset. They also noted that since somatic comorbidity is broadly defined, patients may have multiple diseases compared with the patients with skin psoriasis and no somatic comorbidity who only had 1 recorded disease.

They recommended that future research understand the interaction of clinical severity with somatic comorbidity and PI in patients with psoriasis. They also noted that the findings support use of holistic patient management.

"I would be delighted if our study could support the trend towards a more holistic view on psoriasis care," coauthor Marcus Schmitt-Egenolf, MD, PhD, dermatologist and professor at Ume University, said in a statement. At the doctor's office, lifestyle factors should be discussed in the awareness that individual responsibility may be limited by available personal and community resources. Such an approach may improve the complete triad of psoriasisskin symptoms, somatic and mental health alike.

Reference

Geale K, Henriksson M, Jokinen J, Schmitt-Egenolf M. Association of skin psoriasis and somatic comorbidity with the development of psychiatric illness in a nationwide Swedish study.JAMA Dermatol.Published online June 3, 2020.doi:10.1001/jamadermatol.2020.1398

Go here to see the original:
What Is the Impact of Psoriasis on Patients' Mental Health? - AJMC.com Managed Markets Network

Unforeseen adverse events associated with biotechnological medications for the treatment of psoriasis are not uncommon. Investigators from the University of Bologna in Italy have published evidence-based recommendations on the management of unforeseen events in patients with psoriasis who are treated with these therapies in Dermatologic Therapy.

According to the authors of the paper, the use of biotechnological medications for psoriasis should be avoided during pregnancy and lactation as there is currently a lack of robust data on the safety of these therapies during these times. Based on current evidence, some monoclonal antibodies may cross the placenta after the first trimester. New anti-IL23 and IL1-17 therapies should be avoided because of these concerns.

The authors suggest clinicians should speak with women with psoriasis who have become pregnant about the safety risks associated with biotechnological therapies and should evaluate whether or not to discontinue therapy. Etanercept and certolizumab are cited as agents that may not cross the placental barrier to the embryo and are suggested as safer therapeutic options for moderate-to-severe psoriasis. Few safety data on the use of biotechnologic agents during lactation exist, suggesting clinicians may wish to practice caution when considering these therapies in women who are considering breastfeeding.

The authors recommend clinicians screen patients with psoriasis for latent tuberculosis prior to and during anti-TNF- treatment. Biologic therapies anti-TNF- or anti-IL12/23 may be initiated 1 month following prophylactic therapy for latent tuberculosis, according to guidelines in the US. For patients with psoriasis who have HIV, the authors cited recent expert opinion statements that supported the consideration of anti-TNF-, ustekinumab, and apremilast for patients who have close monitoring and control of HIV load and CD4 count.

In terms of surgical procedures, the authors stated that no interruption of biologic therapy is needed for patients with psoriasis who are set to undergo low-risk interventions. For moderate- and high-risk surgeries, the authors suggest the administration of biologic agents should be stopped 3 to 4 times the half-lives of the therapy prior to intervention. Biologic therapy could be restarted 1 to 2 weeks after surgery if the patient is free from complications.

The authors wrote that any clinician who treats psoriasis with biotechnologic therapy may experience 1 unexpected events, stating that it should be good practice to know how to manage them. Further study is needed to form a consensus-based guideline on how to manage these events in this patient population.

Follow @DermAdvisor

Reference

Sacchelli L, Magnano M, Loi C, Patrizi A, Bardazzi F. The unforeseen during biotechnological therapy for moderatetosevere psoriasis: How to manage pregnancy and breastfeeding, infections from Mycobacterium tuberculosis, hepatitis B virus, hepatitis C virus, and HIV, surgery, vaccinations, diagnosis of malignancy, and dose tapering [published online April 14, 2020]. Dermatol Ther. doi:10.1111/dth.13411

Read more from the original source:
Management Strategies for Unforeseen Events of Psoriasis Biotech Therapies - Dermatology Advisor

Findings of this global survey Beyond the visible: rosacea and psoriasis of the face show that regardless of the disease (rosacea (ROS) or psoriasis of the face (PsO)), almost all (90%) of the patients surveyed felt their disease was partially or totally uncontrolled, and experienced a similar impact on working life, with 40% of sufferers across both diseases admitting that their condition impairs their work activities.1

Over half of patients surveyed felt their disease significantly affected their daily lives (58% ROS vs 55% PsO), with 1 in 2 people self-reporting moderate-to-severe depression (49% ROS vs 54% PsO) and at least a third self-reporting moderate-to-severe anxiety (34% ROS vs 43% PsO).1

However, when it comes to assessing new patients, quality of life (QoL) and psychosocial impact is not top of mind for HCPs, with only a limited number of doctors surveyed mentioning that they investigate QoL issues in practice (9% ROS vs 22% PsO).1

Based on these findings involving over 600 patients with facial skin disease (rosacea or psoriasis)* and 361 doctors across 6 countries, the report explores the challenge of controlling the two diseases, quality of life issues, similarities and disparities in disease management, mental health impacts, as well as HCP attitudes and approaches, with the aim of improving disease outcomes.

Commenting on the findings, Prof. Dr Jerry Tan, Adjunct Professor, Western University, Ontario, Canada, and one of the expert authors of the report says:

"This ground-breaking study is helping to evolve treatment practice in rosacea and psoriasis. There is much to be learned from current practice and the striking similarities between rosacea and psoriasis of the face, in terms of impact on patients' productivity and daily lives, which further demonstrates the importance of improving outcomes."

Invisible symptoms such as stinging, burning and itching are driving disease burden for many sufferers, yet only a quarter of doctors surveyed are routinely assessing these symptoms with their rosacea patients (27% ROS vs 40% PsO).1

Though more than half of all patients in the survey, regardless of disease, were ashamed of their condition, it was rosacea patients that were more likely to blame themselves for flare-ups (28% ROS vs 20% PsO), said they experience low self-esteem (34% ROS vs 20% PsO) and low confidence (30% ROS vs 18% PsO).1

Almost half (46%) of rosacea patients and almost a third (30%) of patients with psoriasis on the face still believed their disease was triggered by lifestyle choices, demonstrating a need for increased patient education.1

The benefits of achieving 'clear' (IGA 0) are well-established in both diseases, and positively, 44% of rosacea patients surveyed recognized that 'clear' skin is possible (vs 35% PsO).1

Encouragingly, the majority of sufferers surveyed expressed a desire to understand more about their disease (73% ROS vs 65% PsO), leading the report's authors to highlight the need for HCPs to empower their patients through knowledge, discuss the invisible as well as visible impacts, and help them to understand the benefits of aiming for 'clear' (IGA 0) to improve outcomes.1

* All patients surveyed claimed to be experiencing a moderate to severe disease impact on their lives

Self-reported, measured using Patient Health Questionnaire-9 (PHQ-9)

Self-reported, measured using General Anxiety Disorder-7 scale (GAD-7)

References:

About rosacea

Rosacea is a common inflammatory skin disease that presents variable clinical characteristics, of which the most common are flushing, persistent erythema, and inflammatory lesions. It mainly affects the central areas of the face, such as the cheeks and nose. The disease can affect both adult men and women, usually after the age of 30. Additionally, symptoms such as stinging, burning and increased sensitivity of the skin are common. The eyes are often affected, and might present as red, dry or itchy.

Although the cause of the disease is still under debate, various trigger factors are known, including spicy foods, alcohol, emotional stress, sun/UV-exposure, hot baths and beverages. Demodex, generally harmless mites, can also be found in the skin in an elevated quantity in people with rosacea.

Rosacea may worsen over time if left untreated. People that suspect they suffer from rosacea should visit their dermatologist or healthcare provider for diagnosis and discuss what treatment is right for them. Because rosacea is a highly visible disease, it is known to cause embarrassment and anxiety in some patients, which in turn may cause frustration and have a negative impact on their social life.

About psoriasis

Psoriasis is a chronic, inflammatory skin disease estimated to affect approximately 125 million people worldwide.3 It ranges in severity from a few scattered red, scaly plaques (lesions), to involvement of almost the entire body surface. It may worsen with age, or wax and wane in its severity.4

Having psoriasis can be a heavy physical, social, emotional and economic burden. It may also increase the risk of developing other conditions like heart disease or diabetes. While there is currently no cure for psoriasis, there is a range of treatment options to alleviate symptoms.3

About Rosacea: Beyond the Visible

Rosacea: Beyond the Visible is a global disease awareness campaign, launched in June 2018 by Galderma. The campaign was initially launched to raise awareness of an expert-authored report highlighting the results of a global market research study involving >700 people with rosacea and >550 physicians, which investigated the true burden of rosacea. The campaign has a dedicated Twitter @Beyond_visible and @Rosacea_beyondthevisible Instagram channel, through which information is shared and those living with rosacea and HCPs are encouraged to participate in conversations about the reality of life with this skin disease.

About Beyond the visible: rosacea and psoriasis of the face

A global market research study involving 300 rosacea patients, 318 patients with psoriasis on the face and 361 doctors in 6 different countries (Canada, France, Germany, Italy, Poland and the USA) investigating their experience of living with, or treating patients living with, rosacea or psoriasis of the face. An expert-authored report of the findings was released in May 2020 and seeks to address three key questions What is the true extent of the burden patients face? How does it differ across the two facial skin diseases? By looking at the impact of facial skin disease from different angles, what insights can we gain to help patients and doctors achieve the best outcomes?

About Galderma

Galderma, the world's largest independent global dermatology company, was created in 1981 and is now present in over 100 countries with an extensive product portfolio of prescription medicines, aesthetics solutions and consumer care products. The company partners with health care practitioners around the world to meet the skin health needs of people throughout their lifetime. Galderma is a leader in research and development of scientifically-defined and medically-proven solutions for the skin. For more information, please visit http://www.galderma.com

Click here to view the survey results infographic: https://mma.prnewswire.com/media/1167325/Galderma_Rosacea_Psoriasis_PDF.pdf

Galderma media relations contact: Sbastien CrosHead of Corporate Communications[emailprotected] +41-21-642-76-94

https://www.galderma.com

SOURCE Galderma

Read this article:
Galderma Global Research Reveals Struggles of People With Rosacea and Psoriasis of the Face Experiencing a Lack of Control and Impact on Mental...

Phase 2 Results of Tildrakizumab Show Significant Joint, Skin Improvements in Adults With Active Psoriatic Arthritis

Tildrakizumab is an IL-23 inhibitor indicated for adults with moderate-to-severe plaque psoriasis and is under investigation for PsA.1

PsA is a chronic, inflammatory disease affecting the joints and places where tendons and ligaments connect to bone.2 The disease leads to inflammation, which causes swelling, pain, and stiffness in the joints, as well as fatigue. PsA affects up to 42% of people with plaque psoriasis in the United States, and typically begins between ages 30 and 50, although it can start at any age.2

Of 500 patients screened for the study, 391 were randomized and received 1 or more doses of the drug. From baseline to week 24, 1 case of pyelonephritis and urinary tract infection and 1 case of chronic tonsillitis was reported. No deaths or major adverse cardiac events occurred.1

In adults with active PsA, the new phase 2 results met primary and secondary efficacy and safety endpoints with statistical significance at week 24. In patients who received tildrakizumab, signs and symptoms including tender and swollen joints, levels of skin clearance, and minimal disease activity response all improved through week 24 and were maintained through week 52. For patients who received 100 mg of the drug, results were seen as early as 8 weeks.1

REFERENCES

Read the original here:
Phase 2 Results of Tildrakizumab Show Significant Joint, Skin Improvements in Adults With Active Psoriatic Arthritis - Pharmacy Times